Abstract
Progressive multifocal leukoencephalopathy (PML) is a life-threatening demyelinating CNS disorder caused by reactivation of JC virus (JCV). Due to profound T-cell depletion and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation (allo-HCT) recipients are at risk for JCV reactivation. Likewise, an increased risk for infectious complications has been reported for patients treated with the anti-CD38 monoclonal antibody daratumumab, potentially attributable to the depletion of NK cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
